Search

Supplementary Material 3. Gender distribution differences between cancer group and normal group

Supplementary Material 3

Supplementary Material 13. The associations between SKP2 expression and immune environment

Supplementary Material 4. The SKP2 expression trends at protein levels in multiple neoplasms

Supplementary Material 10. Identification of covariate between age, gender, and AJCC stage

Supplementary Material 1. THPA samples included in this study for exploring SKP2 protein levels

Supplementary Material 5

Supplementary Material 1

Supplementary Material 16. A summary of KEGG results based on gene set enrichment analysis in this study

Supplementary Material 2

Supplementary Material 4

Supplementary Material 5. The potential association between transcription factor FOXM1 and SKP2 in pan-cancer. Panel A: Expression of FOXM1 was significantly upregulated in 15 human cancer types, as determined by Wilcoxon rank-sum test (multiple comparison test by false discovery rate, **p < 0.01, ***p < 0.001). Panel B: The mRNA expression levels of FOXM1 were positively correlated with those of SKP2 in 15 cancer types (Spearman correlation coefficients are indicated as numerical values). Panel C: ChIP-Seq binding peaks of FOXM1 were observed upstream of SKP2 transcriptional start sites

Supplementary Material 6

Supplementary Material 15. KEGG results based on gene set enrichment analysis in this study

Additional file 2. The data sets included in this study.

Additional file 5. The sensitivity analysis determined the robustness of SMD results.

Additional file 1. Cancer abbreviations and full names contained in the pan-cancer dataset in this study.

Additional file 4. Information of datasets included in the study.

Additional file 9. Immune cell infiltration in high-risk and low-risk groups for each sample.

Additional file 6. There is no significant difference in clinical parameters between high-ITGAV and low-ITGAV expression groups (for disease-free survival).

Objectives To investigate means and effect on surgical treatment of atrial myxoma under superficial hypothermia and cardiopulmonary bypass (CPB) without heart beating cease. Methods Clinical datas and surgical treatment of 64 patients with primary atrial myxoma from January 2003 to March 2012 were retrospectively reviewed. All of atrial myxoma excised under general anesthaesia with superficial low temperature extracorporal circulation on beating heart. Results The CPB time was 19–84 min (mean 44.6±15.2 min). All of 53 cases of left atrial myxoma and 7 cases of right atrial myxoma and four cases of double atrial myxoma were respected successfully and without cerebral embolism or gas embolism etc postoperative complications occurred, and without death in period of operation, they were all myxoma recovered. The patients were followed up for 1 month–9 years with a follow-up rate of 85.9%. All of cases didn9t relapsed after operation nine patients were lost to follow-up. Conclusions Atrial myxoma should be early performed after diagnosis results suggested that intracardiac procedures on pump beating-heart with superficial hypothermia cardiopulmonary bypass is safe and available in patients with atrial myxoma.